Hong Kong Med J 2023;29(Suppl 2):S8-11
Health economic analysis of epidermal growth factor receptor mutation-guided first-line therapies for advanced non-small-cell lung cancer: abridged secondary publication
JHS You1, WCS Cho2, YC Li3, CK Kwan4, JSK Au5
1 School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China
2 Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China
3 Hong Kong United Oncology Centre, Hong Kong SAR, China
4 Department of Oncology, United Christian Hospital, Hong Kong SAR, China
5 Oncology Center, Hong Kong Adventist Hospital, Hong Kong SAR, China
 
 
  1. EGFR mutation-guided use of tyrosine kinase inhibitor (TKI) therapy (afatinib, erlotinib and gefitinib) appears to gain higher quality-adjusted life-years than empirical chemotherapy (without EGFR mutation testing).
  2. The cost-effectiveness of EGFR mutation-guided TKI is highly subject to the cost of TKI therapy and the willingness-to-pay threshold.